NeuroSearch starts clinical trial of Alzheimer's disease treatment  

Neurosearch and Boehringer Ingelheim start Phase 2 trial of promising drug compound NS2330

Danish biopharmaceutical company NeuroSearch and Boehringer Ingelheim are initiating a clinical study in 400 patients suffering from mild to moderate Alzheimer's disease. The study is being carried out carried out in the US and Canada, and is expected to be completed by the end of 2003. The new drug compound, NS2330, enhances the function of neurotransmitters which are impaired in Alzheimer's patients. NS2330 has shown positive results both in preclinical and clinical studies. The news is reported in Jyllands-Posten today.


The World Health Organization (WHO) estimates that around 15 million people worldwide suffer from Alzheimer's disease. The prevalence of the disease doubles every five years beyond the age of 65, and beyond the age of 85 the prevalence is 20%. NeuroSearch is listed on the Copenhagen Stock Exchange and has strategic alliances with a number of companies including Abbott Laboratories, Boehringer Ingelheim, and Organon.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×